Cherwell publishes guide on environmental monitoring processes and validation
Supporting EM programs in preparation for proposed EU GMP Annex 1 changes.
Cherwell Laboratories, specialist supplier of products for environmental monitoring and process validation, has drawn on its in-depth pharmaceutical and related industry knowledge to publish an eBook titled, “The Environmental Monitoring Processes and Validation Guide.”
The new guide (available to download from Cherwell’s website) has been created following the release of the revised draft of EU GMP Annex 1 – Manufacture of Sterile Medicinal Products. It is intended to assist sterile product manufacturers with reviewing and improving their environmental monitoring (EM) programs in preparation for the proposed changes to Annex 1.
The comprehensive guide highlights the most business-efficient EM measures organisations can take to comply with the latest iteration of the EU GMP Annex 1, and practical steps they can take to create the ideal EM process. It also addresses and summarises the key changes proposed to Annex 1 and covers: Why the EU GMP Annex 1 draft has been proposed; how it helps all industries move closer towards a global standard; how to prepare for compliance; examples of best practice for EM programs and the right tools needed for an effective and compliant program.
Andrew Ramage, Cherwell Laboratories’ Microbiology Product Specialist comments: “The draft copy of the new version of EU GMP Annex 1 has considerably more detail on the expectations of designing and implementing an environmental monitoring regime. It remains to be seen how much will change following the public consultation. Regardless of what changes are made, our in-depth guide will help the end user to interpret the new guidelines and to create and implement a robust environmental monitoring regime for their cleanroom, whatever the size of their facility.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.